Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Source: PRNewswire· August 18, 2026
SynaBot summary
Cumulus Neuroscience's NeuLogiq platform has proven effective for at-home cognitive assessments in individuals with ALS and FTD. The study, published in Scientific Reports, highlights the platform's usability even with severe motor and cognitive impairments.
Key takeaways
- At-home cognitive assessment platform shows success in ALS and FTD patients
- NeuLogiq platform demonstrated feasibility with significant motor impairment
- High usability reported by participants with severe cognitive decline
- AI enables remote health monitoring for neurological conditions
Why it matters
This development is significant for AI tool users in healthcare, demonstrating how AI can enable remote patient monitoring and data collection. It suggests future AI applications for assessing cognitive health outside clinical settings, improving accessibility for those with mobility challenges.
This story was reported by PRNewswire. Read the full original article:
Read on PRNewswire 
